Completed PHASE1 INTERVENTIONAL NCT00004062

Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer

Restoration of Radioiodine Uptake in Thyroid Carcinoma: A Clinical Trial

Sponsor: Lucille P. Markey Cancer Center at University of Kentucky

Interventions azacitidine iodine I 131 liothyronine sodium

Updated 5 times since 2017 Last updated: Dec 18, 2013 Started: Jul 31, 1999 Completion: Aug 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Head and Neck Cancer and is currently completed. Lucille P. Markey Cancer Center at University of Kentucky leads this study, which shows 5 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jul 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lucille P. Markey Cancer Center at University of Kentucky
National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lexington, United States